IDO-specific T cells thus lyse IDO+ cancer cell lines of different origins, including melanoma cells and ex vivo–enriched leukemia cells, exemplifying the universal character of TMAs shared among a variety of human cancers. This evidence concerns the gene IDO1 and melanoma.